Published in final edited form as:

Neuroscience. 2010 March 31; 166(3): 864–877. doi:10.1016/j.neuroscience.2010.01.026.

Temporally- and spatially-regulated transcriptional activity of the nicotinic acetylcholine receptor $\beta 4$ subunit gene promoter

Lei Brüsweiler-Li^{1,a}, Yuly F. Fuentes Medel^{1,2}, Michael D. Scofield^{1,3}, Ellen B. T. Trang¹, and Sarah A. Binke¹

¹Brudnick Neuropsychiatric Research Institute, Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA 01604

²Program in Neuroscience, University of Massachusetts Medical School, Worcester, MA 01605

³Interdisciplinary Graduate Program, University of Massachusetts Medical School, Worcester, MA 01605

Abstract

Signaling through nicotinic acetylcholine (nACh) receptors underlies a diverse array of behaviors. In order for appropriate signaling to occur via nACh receptors, it is necessary for the genes encoding the receptor subunits to be expressed in a highly regulated temporal and spatial manner. Here we report a transgenic mouse approach to characterize the transcriptional regulation of the gene encoding the nACh receptor $\beta 4$ subunit. nACh receptors containing this subunit play critical roles in both the central and peripheral nervous systems. We demonstrate that a 2.3-kilobase pair fragment of the $\beta 4$ 5'-flanking region is capable of directing reporter gene expression in transgenic animals. Importantly, the transcriptional activity of the promoter region is cell-type-specific and developmentally regulated and overlaps to a great extent with endogenous $\beta 4$ mRNA expression. These data indicate that the 2.3-kilobase pair fragment contains transcriptional regulatory elements critical for appropriate $\beta 4$ subunit gene expression.

Keywords

nicotinic receptor; gene expression; transcription

Signaling through neuronal nicotinic acetylcholine (nACh) receptors underlies several fundamental biological processes both during development and in the adult (Albuquerque et al., 2009). In the central nervous system, presynaptic nACh receptors modulate release of most classical neurotransmitters including norepinephrine, ACh, glutamate and GABA (Albuquerque et al., 2009; Dani and Bertrand, 2007; Engelman and MacDermott, 2004). Postsynaptic nACh receptors are intimately involved in fast ACh-mediated synaptic transmission in addition to activity-dependent gene expression, which is critical for synaptic

© 2009 IBRO. Published by Elsevier Ltd. All rights reserved.

Corresponding author: Paul D. Gardner, Brudnick Neuropsychiatric Research Institute, Department of Psychiatry, University of Massachusetts Medical School, 303 Belmont Street, Worcester, MA 01604, USA. Telephone: 508-856-4035; Fax: 508-856-4130. paul.gardner@umassmed.edu..

^aPresent address: Department of Chemistry and Biochemistry, National High Magnetic Field Laboratory, Florida State University, Tallahassee, FL, 32310.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

plasticity (Albuquerque et al., 2009; Dani and Bertrand, 2007; Hu et al., 2002; Ji et al., 2001). Within the peripheral nervous system, nACh receptors mediate fast excitatory transmission in most, if not all, autonomic ganglia and are involved in modulating visceral and somatic sensory transmission (Genzen et al., 2001; Hu and Li, 1997; Steen and Reeh, 1993; Sucher et al., 1990; Wang et al., 2002). More recently, numerous studies have revealed the expression of nACh receptors on non-neuronal cells and evidence is accumulating indicating that the receptors play crucial roles in signal transduction underlying many physiological processes outside the nervous system (Gahring and Rogers, 2006; Spindel, 2003; Wessler and Kirkpatrick, 2008). The importance of nACh receptor-mediated signaling is reflected in the many pathologies in which cholinergic signal transduction is compromised. For example, significant alterations in nACh receptor expression and function have been documented in several diseases such as Alzheimer's disease, autosomal dominant nocturnal frontal lobe epilepsy, schizophrenia, Parkinson's disease, Tourette's disease and megacystismicrocolon-intestinal hypoperistalsis syndrome (De Fusco et al., 2000; Isacson et al., 2002; Lena and Changeux, 1997; Perl et al., 2003; Perry et al., 2001; Richardson et al., 2001; Silver et al., 2001; Steinlein et al., 1995; Teaktong et al., 2003; Whitehouse et al., 1988). In addition, nACh receptors are key players in the initial steps and subsequent downstream health consequences of nicotine addiction (Kedmi et al., 2004; Laviolette and van der Kooy, 2004). Significantly, there is a growing awareness that nACh receptors may directly contribute to the pathogenesis of lung cancer (Catassi et al., 2008; Eggleston et al., 2008; Schuller, 2008; Schuller, 2009; Song et al., 2008).

Neuronal nACh receptors are pentameric ligand-gated ion channels assembled from a family of subunits that include $\alpha 2 - \alpha 10$ and $\beta 2 - \beta 4$ (Albuquerque et al., 2009). The $\alpha 2 - \alpha 6$ subunits can form functional receptors in combination with the $\beta 2 - \beta 4$ subunits while the $\alpha 7 - \alpha 10$ subunits are capable of forming homomeric nACh receptors. In addition, the $\alpha 9$ and $\alpha 10$ subunits form unique heteromeric receptors (Elgoyhen et al., 2001; Lustig et al., 2001; Taranda et al., 2009) as do the $\alpha 7$ and $\beta 2$ subunits (Liu et al., 2009). Importantly, each nACh receptor subtype exhibits distinct electrophysiological and pharmacological properties, reflecting the broad array of signaling pathways in which nACh receptors are involved (Albuquerque et al., 2009). The functional diversity exhibited by the neuronal nACh receptor family is a consequence, in part, of the differential expression of the various subunit genes leading to the incorporation of distinct subunits into mature receptors. A major goal in the field is to uncover the molecular mechanisms underlying the temporal and spatial expression of the nACh receptor subunit genes.

Several laboratories, including our own, have focused on elucidating the transcriptional mechanisms regulating expression of the $\alpha 3$, $\alpha 5$ and $\beta 4$ subunit genes. These genes are particularly interesting from a regulatory point-of-view as they are tightly clustered in the genome (Boulter et al., 1990), perhaps reflecting their coordinate regulation. Several lines of evidence support this hypothesis. First, the three subunits have extensively overlapping expression patterns (Azam et al., 2002; Dineley-Miller and Patrick, 1992; Gahring et al., 2004; Genzen et al., 2001; Hellström-Lindahl et al., 1998; Keiger et al., 2003; Liu et al., 1998; Rust et al., 1994; Vincler and Eisenach, 2003; Winzer-Serhan and Leslie, 1997; Zoli et al., 1995). Second, the promoter regions of the $\alpha 3$, $\alpha 5$ and $\beta 4$ subunit genes can all directly interact with and be trans-activated by the widely expressed transcription factors Sp1 and Sp3 (Bigger et al., 1996; Bigger et al., 1997; Boyd, 1996; Campos-Caro et al., 1999; Valor et al., 2002; Yang et al., 1995) and the more spatially-restricted regulatory factors Sox10 and SCIP/Tst-1/Oct-6 (Fyodorov and Deneris, 1996; Liu et al., 1999; Yang et al., 1994). Third, $\alpha 3$, $\alpha 5$ and $\beta 4$ mRNA levels are coordinately up-regulated during neural development (Corriveau and Berg, 1993; Levey et al., 1995; Levey and Jacob, 1996) and coordinately down-regulated following denervation (Zhou et al., 1998). Finally, two transcriptional regulatory elements, $\beta 43'$ and CNR4, have been shown to play key roles in directing expression of the clustered

nACh receptor genes in a tissue-specific manner with $\beta 43'$ being important for expression in the adrenal gland and CNR4 being critical for expression in the pineal gland and superior cervical ganglion (Xu et al., 2006). CNR4 also appears to play a role in directing nACh receptor expression in the brain (Xu et al., 2006).

While these advances have shed considerable light on the molecular details of nACh receptor expression, it is likely that *cis* elements in addition to $\beta 43'$ and CNR4 are involved in regulating clustered gene expression in the nervous system given that neither of these elements completely recapitulated receptor gene expression in vivo (Xu et al., 2006). Here we describe a transgenic mouse approach in which a 2.3-kilobase pair region of the nACh receptor $\beta 4$ subunit 5'-flanking DNA was used to drive expression of β -galactosidase (β -gal). This region of the $\beta 4$ subunit gene contains several regulatory elements we previously showed to direct cell-type-specific expression in vitro (Liu et al., 1999). The present work demonstrates that this region also directs spatially restricted expression in vivo and further, that this regulatory function is developmentally regulated.

Experimental Procedures

Construction of the $\beta 4$ promoter/ β -galactosidase transgene

A 2,346-base pair SstI/HindIII fragment of the rat $\beta 4$ subunit gene was treated with Klenow fragment of DNA polymerase I to generate blunt ends. This fragment spans nucleotides -2208 to +137 relative to the $\beta 4$ transcription initiation site (Hu et al., 1994). The blunt-ended SstI/HindIII fragment was subcloned into the β -gal expression vector, pSG-MAR, which had been digested with SmaI, to generate the construct pSGB4SH (Fig. 1B). pSG-MAR contains the β -gal coding sequence, a nuclear localization signal (NLS) as well as the 5' matrix attachment region (MAR) of the chick lysozyme gene (Fuchs et al., 2002). The NLS was included to facilitate comparison between β -gal activity with $\beta 4$ RNA expression and to reduce background staining (Mercer et al., 1991). The MAR was included to insulate the transgene from insertion positional effects (Phi-Van and Stratling, 1996). The construct was verified by nucleotide sequencing (Nucleic Acid Facility, University of Massachusetts Medical School).

Cell culture and transfection

The rat pheochromocytoma cell line, PC12 (Greene and Tischler, 1976), was cultured and transfected as previously described (Liu et al., 1999). Briefly, the transfections were done using a liposome-mediated approach (Lipofectamine, Invitrogen, California, USA). The cells were transfected with pSGB4SH and a luciferase expression construct, pGL-Promoter (Promega Corporation, Wisconsin, USA). The cells were differentiated with 100 ng/ml nerve growth factor (NGF; Upstate Biotechnologies, Inc., New York, USA) for 2 days following transfection and then harvested and assayed for β -gal (Galacto-Star, Applied Biosystems, California, USA) and luciferase (Luciferase Assay System, Promega) activities in a Lumimark microplate luminometer (Bio-Rad, California, USA). To correct for differences in transfection efficiencies between dishes, the β -gal activity in each sample was normalized to the luciferase activity in that same sample.

Generation of transgenic mice

pSGB4SH was digested with NotI to release the $\beta 4/\beta$ -gal transgene (Fig. 1B). Following agarose gel electrophoresis, the transgene fragment was excised and the DNA was extracted from the gel using a QIAquick Gel Extraction Kit (QIAGEN, California, USA). The purified DNA was injected into pronuclei followed by implantation into pseudopregnant females. The C57BL/6 $\times$ SJL F2 hybrid mouse strain was used for all transgenic experiments. Injection of DNA and all subsequent steps up to and including the generation of founder animals were performed by the University of Massachusetts Medical School Transgenic Animal Modeling

Core. Transgenic founders were identified by polymerase chain reaction. Founders were mated with C57BL/6 × SJL F2 hybrid mice to establish transgenic lines. Adequate measures were taken to minimize pain and discomfort to the animals. All procedures were conducted in accordance with the rules of the Institutional Animal Care and Use Committee of the University of Massachusetts Medical School.

Determination of transgene copy number

Transgene copy number of the 4 transgenic lines was determined using absolute quantification-based real-time PCR (Yuan et al., 2007). PCR reactions were performed with primers designed to amplify a fragment of the β -gal coding sequence present in the β 4 promoter/ β -gal transgene. The sequence of the upper strand primer was 5'-GATTTCATGTTGCCACTCGCTTTA-3' while that of the lower strand primer was 5'-TTCAGCAGCAGCAGACCATTTCCTAA-3'. All PCR reactions were set up in triplicate and included 100 nanograms of genomic DNA as template. Two positive control samples of known copy number (a generous gift from Ricardo Medina) were used in this analysis. These control samples were isolated from transgenic animals that contain a targeted β -gal coding sequence. One of these animals has 1 copy of the β -gal transgene and the other has 2 copies. The value obtained for the single copy positive control sample was set as 1 in each experiment. This value was used to estimate the copy number for all other samples including the control sample with 2 copies. In quadruplicate assays run with the 2-copy control, transgene copy numbers ranged from 2.005 to 2.274 with an average value of 2.07. In order to determine copy number for our 4 β 4/ β -gal transgenic lines, 3 DNA samples from each line were run in qPCR experiments. The quantities derived from the standard curve for each set of 3 animals were averaged and then divided by the value for the 1-copy positive control.

Histochemical analysis of transgenic mice

Two ages of transgenic mice were studied: embryonic day (ED) 18.5 and postnatal day (PD) 30. Mice were anesthetized with pentobarbital and perfused transcardially with cold 0.1 M sodium phosphate buffer/2 mM MgCl_2 followed by fixative (cold 4% paraformaldehyde). Tissues were then dissected and post-fixed for 5-6 hours (ED18.5) or 4 hours (PD30). Fixed tissues were transferred to 30% sucrose/2 mM MgCl_2 , in 1X phosphate-buffered saline (PBS) and incubated at 4°C overnight. Tissues were embedded in Tissue-Tek (Miles, Indiana, USA) and quick frozen on dry ice. If not used immediately, the samples were stored at -70°C. Sectioning was done on a Leica CM3050S cryostat at -30°C generating either 14 μm (ED18.5) or 25 μm (PD30) thick sections that were transferred directly onto Superfrost glass slides (Fisher, Pennsylvania, USA). Slides were air-dried at room temperature, washed with sodium phosphate buffer and then incubated overnight at 37°C with β -gal staining solution (0.1 M NaH_2PO_4 , 0.1 M NaH_2PO_4 , 2 mM MgCl_2 , 0.1% sodium deoxycholate, 0.02% NP-40, 10 mM $\text{K}_3(\text{Fe})\text{CN}_6$, 10 mM $\text{K}_4(\text{Fe})\text{CN}_6$, 1 mg/ml X-gal). The slides were subsequently washed with 1X PBS and incubated with distilled water either for 1 hour (ED18.5) or overnight (PD30). Slides were then counter-stained with Neutral Red (1% w/v in 37 mM sodium acetate), dehydrated through a graded series of ethanol (50%, 70%, 90% and 100%) and cleared with xylene. The slides were air-dried overnight at room temperature in a fume hood followed by the application of cover slips. Microscopy was done using a Zeiss Axiovert 200M microscope with a high resolution Retiga 1300R CCD camera and Slidebook image analysis software. Anatomical analysis was done with the aid of Kaufman (Kaufman, 1995) and Paxinos and Franklin (Paxinos and Franklin, 2001).

Triple Immunofluorescence

Slides were prepared as described above for the PD30 animals (25- μm sections). The samples were washed twice for 10 minutes in 1X PBS then permeabilized for 20 minutes in 0.1% Triton

X-100 in PBS. Following 3 washes in PBS, the sections were incubated with 1% BSA in PBS for 3 hours. The BSA solution was removed and the sections were incubated overnight with primary antibodies. The antibodies and their dilutions were as follows: rabbit anti- β -gal (1:100; MP Biomedicals, Ohio, USA), mouse anti-neuron-specific nuclear marker (NeuN; 1:100; Millipore, Massachusetts, USA) and chicken anti-glial fibrillary acid protein (GFAP; 1:500; Millipore). The dilutions were made with 1% BSA in PBS. After antibody incubation, the slides were washed 5 times for 6 minutes with 1X PBS followed by a 2-hour incubation with a 1:100 dilution of each secondary antibody. The following antibodies were used (all from Invitrogen, California, USA): Alexa 488 (goat anti-rabbit), Alexa 350 (goat anti-mouse IgG1) and Alexa 594 (goat anti-chicken). The sections were washed 5 times for 10 minutes with 1X PBS and mounted with Vectashield (Vector Laboratories, California, USA). Microscopy was done as described above.

Results and Discussion

In vitro functional characterization of the $\beta 4/\beta$ -galactosidase transgenic construct

An approximately 2.3-kilobase pair fragment of the nACh receptor $\beta 4$ subunit 5'-flanking DNA (Fig. 1A) was subcloned into the β -gal expression vector, pSG-MAR (Fuchs et al., 2002) generating the construct pSGB4SH (Fig. 1B). This region of the $\beta 4$ promoter contains two transcriptional regulatory elements we previously characterized in vitro in the context of a luciferase-based reporter vector. These elements are referred to as a CT box and a CA box based on their nucleotide compositions (Fig. 1C). The 19-base pair CT box contains 3 repeats of the sequence 5'-CCCT-3' (Hu et al., 1995) and directly interacts with the regulatory factors heterogeneous nuclear ribonucleoprotein K and Pur α (Du et al., 1998; Du et al., 1997). The CA box (5'-CCACCCC-3') directly interacts with the general transcription factors Sp1 and Sp3 (Bigger et al., 1996; Bigger et al., 1997) and the more spatially-restricted factor Sox10 (Liu et al., 1999). To confirm that the transcriptional activity of pSGB4SH, a β -gal-based system, is similar to that of the previous $\beta 4$ /luciferase constructs, transient transfections were carried out using the rat pheochromocytoma cell line, PC12 (Greene and Tischler, 1976). pSGB4SH was transfected into parallel cultures of PC12 cells with one set of cells being treated with NGF for 2 days following transfection and the other set being used as untreated controls. As shown in Figure 1D, there was a significant increase in β -gal activity following NGF treatment reflecting an increase in $\beta 4$ promoter activity. These data are consistent with our previous work using the luciferase-based reporter vector (Hu et al., 1994; Liu et al., 1999) and indicated that the new construct was suitable for transgenic work.

$\beta 4$ promoter activity in ED18.5 transgenic mouse embryos

To determine whether the 2.3-kilobase pair $\beta 4$ promoter region functions in vivo and if so, in a cell-type-specific manner reflecting endogenous $\beta 4$ mRNA expression, the $\beta 4/\beta$ -gal transgene was excised from the pSGB4SH backbone and used to generate several founder lines of mice (see *Experimental Procedures* for details). Nine founder lines were obtained. Of these, 1 died unexpectedly, 1 showed no β -gal staining, 2 did not breed well and 1 showed extremely intense β -gal staining throughout the body and was not pursued. The remaining 4 lines (lines 30, 39, 54 and 447) were analyzed for β -gal staining at ED18.5 and PD30 as described below. Using a quantitative PCR approach (Yuan et al., 2007), transgene copy number was determined for each line and revealed that line 30 has approximately 7 copies, line 39 has 26 copies, line 54 has 12 copies and line 447 has 10 copies (see *Experimental Procedures* for details).

In general, β -gal staining was substantially less intense in embryos as compared to adults for all four founder lines indicating a developmental effect on $\beta 4$ promoter activity. In fact, founder lines 30 and 39 showed almost no detectable staining in the central nervous system at ED18.5 but showed extensive staining at 1 month of age (see below). The two other lines (lines 54 and

447) however, did exhibit significant β -gal staining early in development, but again, the staining was more intense in older animals (see below). As shown in Figures 2 - 4, the $\beta 4$ promoter region directs rather striking cell-type-specific expression of the β -gal gene in ED18.5 transgenic embryos of founder lines 54 and 447. In the central nervous system, there is very strong β -gal staining in the cortex (intermediate and ventricular zones, Fig. 2A), the medulla oblongata (Fig. 2C), the pons (Fig. 2E) and the spinal cord (Fig. 2G, I and K). Less intense staining is seen in other regions of the central nervous system including the piriform cortex, subiculum, lateral and medial habenular nuclei and the pontine area (Table 1). These results are consistent with in situ work done by others characterizing expression of endogenous $\beta 4$ mRNA (Winzer-Serhan and Leslie, 1997; Zoli et al., 1995). In addition to these regions, endogenous $\beta 4$ mRNA has been detected in the pineal gland. Our transgene construct did not yield β -gal expression in this region. This is most likely due to the absence of CNR4, a transcriptional regulatory region shown by the Deneris group to be important for pineal gland expression of the clustered nACh receptor genes (Xu et al., 2006). CNR4 is located several kilobase pairs upstream of the $\beta 4$ promoter region being tested in this work (Xu et al., 2006).

Outside of the central nervous system, there was remarkable β -gal staining in the spinal ganglia (Fig. 3), the intestine (Fig. 4A) and the tongue (Fig. 4C) of ED18.5 transgenic animals. There were lower levels of β -gal staining in the retina, trigeminal ganglia and lips (Table 2). Again, for the most part, these results are consistent with $\beta 4$ mRNA localization studies (Winzer-Serhan and Leslie, 1997; Zoli et al., 1995). Two notable exceptions are the intestine and the lips, for which we are not aware of any reports describing the presence of $\beta 4$ mRNA in ED18.5 animals. The presence of β -gal staining in these areas may be due to positional effects on transgene expression or it could be due to the lack of a cell-type-specific repressor element we previously identified in an intron of the nACh receptor $\alpha 3$ subunit gene, which we showed represses $\beta 4$ promoter activity in cells that do not express the $\beta 4$ subunit gene (Fuentes Medel and Gardner, 2007).

$\beta 4$ promoter activity in the brains of transgenic PD30 mice

As mentioned above, in contrast to embryonic animals, all four founder lines exhibited significant β -gal staining at one month of age. Analysis of β -gal staining revealed broad and substantial $\beta 4$ promoter activity in the brains of transgenic animals. In particular, there was significant staining in the cortex, hippocampus, thalamus, amygdala, medial habenula and the colliculus. For the most part, the broad β -gal staining (Table 3) is consistent with previous studies that determined $\beta 4$ subunit mRNA expression using in situ hybridization (Azam et al., 2002; Dineley-Miller and Patrick, 1992; Winzer-Serhan and Leslie, 1997). In addition, the present results are consistent with immunostaining work that indicated widely dispersed expression of the nACh receptor $\beta 4$ subunit protein in the adult mouse nervous system (Gahring et al., 2004). As discussed by Gahring et al., the regulated widespread expression of the $\beta 4$ subunit gene likely reflects its role in a variety of diverse functions in the nervous system.

Forebrain/cortex—As with nACh receptor $\beta 4$ mRNA (Dineley-Miller and Patrick, 1992; Winzer-Serhan and Leslie, 1997) and protein (Gahring et al., 2004), significant $\beta 4$ promoter activity was detected in layer 5 of the cortex (Fig. 5A) and the piriform cortex (Fig. 5C). Slightly lower promoter activity was observed in the frontal association cortex and caudate putamen (Fig. 5E and G, respectively) with there being lower levels in the cingulate/retrosplenial cortex (Fig. 5I). There was also substantial $\beta 4$ promoter activity in other regions of the forebrain/cortex (Table 3) including the olfactory bulb, agranular insular cortex, auditory cortex, cingulate/retrosplenial cortex, piriform cortex and the visual cortex, amongst others. In addition, there were regions where $\beta 4$ promoter activity was seen for which we know of no reports of $\beta 4$ mRNA expression, such as the entorhinal, orbital and prelimbic cortices (Table 3). Again, this may be due to the lack of other transcriptional regulatory elements in the $\beta 4$ /

β -gal transgene, such as the cell-type-specific repressor element discussed above. Alternatively, it could be due to positional effects on transgene expression.

Hippocampus/Subiculum—The hippocampus is an interesting region in which to study nACh receptor $\beta 4$ expression, as it is known that $\beta 4$ expression in this structure significantly varies across mouse strains (Gahring et al., 2004). However, it is clear that across strains, there is $\beta 4$ expression, both mRNA and protein, in the dentate gyrus, CA1 field, CA3 field and the subiculum (Dineley-Miller and Patrick, 1992; Gahring et al., 2004; Winzer-Serhan and Leslie, 1997). Consistent with these observations, we see strong $\beta 4$ promoter activity in these same regions (Fig. 6A and Table 3).

Habenular Nuclei—The habenula is the region of highest nACh receptor $\beta 4$ subunit expression in the brain (Dineley-Miller and Patrick, 1992; Duvoisin et al., 1989; Gahring et al., 2004; Winzer-Serhan and Leslie, 1997). As expected, $\beta 4$ promoter activity was quite strong in the medial habenula, but was lower in the lateral habenula (Fig. 6C). Interestingly, $\beta 4$ promoter activity was much higher in PD30 animals versus ED18.5 animals. This is in contrast to $\beta 4$ mRNA levels - which are high throughout development (Winzer-Serhan and Leslie, 1997; Zoli et al., 1995) - and may reflect the absence of other regulatory elements in the $\beta 4$ / β -gal transgene, for example, CNR4, that may be active early in development (Xu et al., 2006).

Thalamus/Hypothalamus—As discussed above, significant $\beta 4$ promoter activity was observed in the medial habenula, a region that expresses high levels of $\beta 4$ mRNA. In addition, the $\beta 4$ subunit is also expressed in the paraventricular thalamic nucleus, medial geniculate nucleus, the posterior thalamic nuclear group, the retroparaventricular nucleus, the inferior colliculus and the ventral anterior and ventral posteromedial thalamic nuclei (Gahring et al., 2004). We detected $\beta 4$ promoter activity in these same regions (Fig. 6C and E and Table 3). With the exception of these structures and the interpeduncular nucleus (see below), nACh receptor $\beta 4$ expression is either very low or undetectable in the thalamus and hypothalamus (Dineley-Miller and Patrick, 1992; Duvoisin et al., 1989; Gahring et al., 2004; Winzer-Serhan and Leslie, 1997). Thus, it was surprising to observe significant $\beta 4$ promoter activity in both of these regions (Table 3). Again, this could be due to the absence of the cell-type-specific repressor element mentioned earlier. Interestingly, while $\beta 4$ mRNA and protein expression is high in the interpeduncular nucleus (Dineley-Miller and Patrick, 1992; Gahring et al., 2004; Winzer-Serhan and Leslie, 1997), we detected no $\beta 4$ promoter activity in this region (not shown). However, Deneris and colleagues reported that CNR4 drives high transgene expression in the interpeduncular nucleus (Xu et al., 2006). The absence of CNR4 in the $\beta 4$ / β -gal transgene used in the current study may explain why no $\beta 4$ promoter activity was seen in this nucleus.

Amygdala and Pons—Two other brain regions of the PD30 mouse where significant $\beta 4$ promoter activity was detected are the amygdala and the pons. In particular, strong $\beta 4$ promoter activity was seen in the posteromedial cortical amygdaloid nucleus (Fig. 6G) and the posterolateral cortical amygdaloid nucleus (Table 3). Lower, yet significant, $\beta 4$ promoter activity was observed in the pons, most notably in the laterodorsal tegmental nucleus, the lateral mammillary nucleus and the lateral parabrachial nucleus (ventral part) as well as in the medial lemniscus (Table 3). To our knowledge, the amygdala and pons have not been reported to express the nACh receptor $\beta 4$ subunit, once more raising the issue as to why $\beta 4$ promoter activity is seen in these two brain regions in multiple founder lines. As before, one possibility is the lack of a cell-type-specific repressor element in the $\beta 4$ / β -gal transgene (Fuentes Medel and Gardner, 2007), although it is possible that the endogenous promoter is subject to regulation, negative in this case, to which the transgene promoter is immune.

The $\beta 4$ promoter is active in neurons

Expression of nACh receptor $\beta 4$ subunit protein has been detected in non-neuronal cells within the brain (Gahring et al., 2004). In order to determine if the $\beta 4$ promoter activity we observed throughout the brain is or is not neuron-specific, triple immunofluorescence was carried out using anti-GFAP to label glial cells, anti-NeuN to label neurons and anti- β -gal to label β -gal-expressing cells. As shown in Figure 7, in each region tested, β -gal labeling over-lapped that of NeuN but not GFAP, indicating that the transgene $\beta 4$ promoter activity is neuron-specific. This suggests that other regulatory elements are involved in the non-neuronal expression of the $\beta 4$ subunit described by Gahring et al. (2004). Alternatively, post-transcriptional or epigenetic regulatory mechanisms may be at work in non-neuronal cells.

In summary, we have used a transgenic mouse model to study the transcriptional activity of the nACh receptor $\beta 4$ subunit gene promoter. As described above, the activity of the $\beta 4/\beta$ -gal transgene used in this study paralleled, for the most part, endogenous $\beta 4$ subunit mRNA expression both spatially and temporally. These results indicate that the 2.3-kilobase pair fragment of the nACh receptor $\beta 4$ subunit 5'-flanking DNA contains transcriptional regulatory elements critical for appropriate cell-type-specific and developmentally regulated expression of the $\beta 4$ subunit gene. Although the precise regulatory elements within the 2.3-kilobase pair region responsible for the *in vivo* activity of the $\beta 4$ promoter have not been determined, strong candidates are the CT and CA boxes that we previously characterized in cell culture systems. The significance of these elements *in vivo* is currently being pursued. However, it is clear that the 2.3-kilobase pair fragment does not contain all of the required positive regulatory elements that govern expression of the $\beta 4$ gene, as there are regions of the brain that express relatively high levels of the $\beta 4$ gene but in which no transgene activity was detected. In some cases, as described above, this may be due to the absence of specific regulatory elements in the transgene used in the present study. For example, the CNR4 element identified by the Deneris group and shown to drive transgene expression in the pineal gland, adrenal gland and specific regions of the brain, was not part of the transgene construct. It is also possible that other, yet to be identified positive regulatory elements are also required for appropriate $\beta 4$ gene expression. In addition to the $\beta 4$ promoter activity that corresponds to endogenous $\beta 4$ mRNA expression, we also detected promoter activity in brain regions that have not been reported to express the $\beta 4$ subunit. These observations likely underscore the importance of negative regulatory elements in $\beta 4$ gene expression and may be a consequence of the absence of a cell-type-specific repressor in the transgene used in this study. We previously demonstrated *in vitro* that this repressor, referred to as “ $\alpha 3$ intron 5”, exerts its transcriptional effects in non- $\beta 4$ -expressing cells but is relatively inactive in $\beta 4$ -expressing cells (Fuentes Medel and Gardner, 2007).

Finally, it is important to note that at least two other modes of regulation are likely to play key roles in expression of the nACh receptor $\beta 4$ subunit gene (as well as other nACh receptor subunit genes). First, in addition to the *cis*-acting elements described thus far, chromatin remodeling most probably is critical for appropriate $\beta 4$ gene expression. This is a relatively understudied area in terms of nACh receptor gene expression and is a focus of current research efforts. Second, post-transcriptional mechanisms are another level of control of nACh receptor expression, particularly in response to extracellular stimuli. One such mechanism may involve small 21-24 nucleotide long regulatory molecules, referred to as microRNAs (miRNAs) (Ambros, 2004). miRNAs are predicted to regulate the majority of mammalian protein-coding genes, typically by binding to complementary sites in the 3'-untranslated regions of target mRNAs and guiding them to an RNA-induced silencing complex (Kosik, 2006). Interestingly, a miRNA, miR-1, has been reported to target nACh receptors in *C. elegans*, leading to changes in nACh receptor properties (Simon et al., 2008). We are investigating whether miRNAs play a role in the expression of mammalian nACh receptor genes.

Acknowledgments

We thank Steve Jones, Joe Gosselin and their colleagues in the UMMS Transgenic Animal Modeling Core for their outstanding services in generating the majority of the transgenic mice used in this study. We also thank Haley Melikian for her help with the microscopy, Monica Carrasco for help with the immunofluorescence, Stéphane Germain for the kind gift of pSG-MAR, Ricardo Medina for providing useful advice and reagents for determining transgene copy number and Irena N. Melnikova for critical review of the manuscript. We acknowledge E.I. Ginns, D. Faryna and C. Dickinson for generating founder line 447. This work was supported by Grant Number R01NS030243 from the National Institute of Neurological Disorders and Stroke. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health.

Abbreviations

nACh	nicotinic acetylcholine
β-gal	β-galactosidase
NLS	nuclear localization signal
MAR	matrix attachment region
NGF	nerve growth factor
ED	embryonic day
PD	postnatal day
PBS	phosphate-buffered saline
NeuN	neuron-specific nuclear marker
GFAP	glial fibrillary acid protein
miRNAs	microRNAs
IZ	intermediate zone
VZ	ventricular zone
M	medulla oblongata
P	pons
DRG	dorsal root ganglion
CDRG	cervical dorsal root ganglion
LRG	lumber root ganglion
CRG	cervical root ganglion
Pir	piriform cortex
FrA	frontal association cortex
Cpu	caudate putamen
Cg/Rs	cingulate/retrosplenial cortex
DG	dentate gyrus
MHb	medial habenula
LHb	lateral habenula
PV	paraventricular thalamic nucleus
VA	ventral anterior thalamic nucleus

PMCo posteromedial cortical amygdaloid nucleus

References

- Albuquerque EX, Pereira EFR, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: From structure to function. *Physiol Rev* 2009;89:73–120. [PubMed: 19126755]
- Ambros V. The functions of animal microRNAs. *Nature* 2004;431:350–355. [PubMed: 15372042]
- Azam L, Winzer-Serhan UH, Chen Y, Leslie FM. Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons. *J Comp Neurol* 2002;444:260–274. [PubMed: 11840479]
- Bigger CB, Casanova EA, Gardner PD. Transcriptional regulation of neuronal nicotinic acetylcholine receptor genes. Functional interactions between Sp1 and the rat beta4 subunit gene promoter. *J Biol Chem* 1996;271:32842–32848. [PubMed: 8955122]
- Bigger CB, Melnikova IN, Gardner PD. Sp1 and Sp3 regulate expression of the neuronal nicotinic acetylcholine receptor β 4 subunit gene. *J Biol Chem* 1997;272:25976–25982. [PubMed: 9325332]
- Boulter J, O'Shea-Greenfield A, Duvoisin RM, Connolly JG, Wada E, Jensen A, Gardner PD, Ballivet M, Deneris ES, McKinnon D, et al. Alpha 3, alpha 5, and beta 4: three members of the rat neuronal nicotinic acetylcholine receptor-related gene family form a gene cluster. *J Biol Chem* 1990;265:4472–4482. [PubMed: 1689727]
- Boyd RT. Transcriptional regulation and cell specificity determinants of the rat nicotinic acetylcholine receptor alpha 3 gene. *Neurosci Lett* 1996;208:73–76. [PubMed: 8859893]
- Campos-Caro A, Carrasco-Serrano C, Valor LM, Viniegra S, Ballesta JJ, Criado M. Multiple functional Sp1 domains in the minimal promoter region of the neuronal nicotinic receptor alpha5 subunit gene. *J Biol Chem* 1999;274:4693–4701. [PubMed: 9988706]
- Catassi A, Servent D, Paleari L, Cesario A, Russo P. Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. *Mutat Res* 2008;659:221–231. [PubMed: 18495523]
- Corriveau RA, Berg DK. Coexpression of multiple acetylcholine receptor genes in neurons: quantitation of transcripts during development. *J Neurosci* 1993;13:2662–2671. [PubMed: 8501530]
- Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. *Annu Rev Pharmacol Toxicol* 2007;47:699–729. [PubMed: 17009926]
- De Fusco M, Becchetti A, Patrignani A, Annesi G, Gambardella A, Quattrone A, Ballabio A, Wanke E, Casari G. The nicotinic receptor beta 2 subunit is mutant in nocturnal frontal lobe epilepsy. *Nat Genet* 2000;26:275–276. [PubMed: 11062464]
- Dineley-Miller K, Patrick J. Gene transcripts for the nicotinic acetylcholine receptor subunit, beta4, are distributed in multiple areas of the rat central nervous system. *Brain Res Mol Brain Res* 1992;16:339–344. [PubMed: 1337943]
- Du Q, Melnikova IN, Gardner PD. Differential effects of heterogeneous nuclear ribonucleoprotein K on Sp1- and Sp3-mediated transcriptional activation of a neuronal nicotinic acetylcholine receptor promoter. *J Biol Chem* 1998;273:19877–19883. [PubMed: 9677424]
- Du Q, Tomkinson AE, Gardner PD. Transcriptional regulation of neuronal nicotinic acetylcholine receptor genes. A possible role for the DNA-binding protein Puralpha. *J Biol Chem* 1997;272:14990–14995. [PubMed: 9169473]
- Duvoisin RM, Deneris ES, Patrick J, Heinemann S. The functional diversity of the neuronal nicotinic acetylcholine receptors is increased by a novel subunit: beta 4. *Neuron* 1989;3:487–496. [PubMed: 2642007]
- Egleton RD, Brown KC, Dasgupta P. Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis. *Trends Pharmacol Sci* 2008;29:151–158. [PubMed: 18262664]
- Elgoyhen AB, Vetter DE, Katz E, Rothlin CV, Heinemann SF, Boulter J. alpha10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. *Proc Natl Acad Sci U S A* 2001;98:3501–3506. [PubMed: 11248107]

- Engelman HS, MacDermott AB. Presynaptic ionotropic receptors and control of transmitter release. *Nat Rev Neurosci* 2004;5:135–145. [PubMed: 14735116]
- Fuchs S, Germain S, Philippe J, Corvol P, Pinet F. Expression of renin in large arteries outside the kidney revealed by human renin promoter/LacZ transgenic mouse. *Am J Pathol* 2002;161:717–725. [PubMed: 12163396]
- Fuentes Medel YF, Gardner PD. Transcriptional repression by a conserved intronic sequence in the nicotinic receptor $\alpha 3$ subunit gene. *J Biol Chem* 2007;282:19062–19070. [PubMed: 17504758]
- Fyodorov D, Deneris E. The POU domain of SCIP/Tst-1/Oct-6 is sufficient for activation of an acetylcholine receptor promoter. *Mol Cell Biol* 1996;16:5004–5014. [PubMed: 8756659]
- Gahring LC, Persiyanov K, Rogers SW. Neuronal and astrocyte expression of nicotinic receptor subunit $\beta 4$ in the adult mouse brain. *J Comp Neurol* 2004;468:322–333. [PubMed: 14681928]
- Gahring LC, Rogers SW. Neuronal nicotinic acetylcholine receptor expression and function on nonneuronal cells. *AAPS Journal* 2006;7:E885–E894. [PubMed: 16594641]
- Genzen JR, Van Cleve W, McGehee DS. Dorsal root ganglion neurons express multiple nicotinic acetylcholine receptor subtypes. *J Neurophysiol* 2001;86:1773–1782. [PubMed: 11600638]
- Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. *Proc Natl Acad Sci U S A* 1976;73:2424–2428. [PubMed: 1065897]
- Hellström-Lindahl E, Gorbounova O, Seiger Å, Mousavi M, Nordberg A. Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. *Develop Brain Res* 1998;108:147–160.
- Hu HZ, Li ZW. Modulation of nicotinic ACh-, GABAA- and 5-HT₃-receptor functions by external H-7, a protein kinase inhibitor, in rat sensory neurones. *Br J Pharmacol* 1997;122:1195–1201. [PubMed: 9401786]
- Hu M, Bigger CB, Gardner PD. A novel regulatory element of a nicotinic acetylcholine receptor gene interacts with a DNA binding activity enriched in rat brain. *J Biol Chem* 1995;270:4497–4502. [PubMed: 7876217]
- Hu M, Liu QS, Chang KT, Berg DK. Nicotinic regulation of CREB activation in hippocampal neurons by glutamatergic and nonglutamatergic pathways. *Mol Cell Neurosci* 2002;21:616–625. [PubMed: 12504594]
- Hu M, Whiting Theobald NL, Gardner PD. Nerve growth factor increases the transcriptional activity of the rat neuronal nicotinic acetylcholine receptor beta 4 subunit promoter in transfected PC12 cells. *J Neurochem* 1994;62:392–395. [PubMed: 7505316]
- Isacson O, Seo H, Lin L, Albeck D, Granholm AC. Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. *Trends Neurosci* 2002;25:79–84. [PubMed: 11814559]
- Ji D, Lape R, Dani JA. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. *Neuron* 2001;31:131–141. [PubMed: 11498056]
- Kaufman, MH. *The Atlas of Mouse Development*. revised edition. Academic Press; San Diego: 1995.
- Kedmi M, Beaudet AL, Orr-Urtreger A. Mice lacking neuronal nicotinic acetylcholine receptor $\beta 4$ -subunit and mice lacking both $\alpha 5$ - and $\beta 4$ -subunits are highly resistant to nicotine-induced seizures. *Physiol Genomics* 2004;17:221–229. [PubMed: 14996991]
- Keiger CJH, Prevette D, Conroy WG, Oppenheim RW. Developmental expression of nicotinic receptors in the chick and human spinal cord. *J Comp Neurol* 2003;455:86–99. [PubMed: 12454998]
- Kosik K. The neuronal microRNA system. *Nat Rev Neurosci* 2006;7:911–920. [PubMed: 17115073]
- Laviolette SR, van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. *Nat Rev Neurosci* 2004;5:55–65. [PubMed: 14708004]
- Lena C, Changeux JP. Pathological mutations of nicotinic receptors and nicotine-based therapies for brain disorders. *Curr Opin Neurobiol* 1997;7:674–682. [PubMed: 9384554]
- Levey MS, Brumwell CL, Dryer SE, Jacob MH. Innervation and target tissue interactions differentially regulate acetylcholine receptor subunit mRNA levels in developing neurons in situ. *Neuron* 1995;14:153–162. [PubMed: 7826633]

- Levey MS, Jacob MH. Changes in the regulatory effects of cell-cell interactions on neuronal AChR subunit transcript levels after synapse formation. *J Neurosci* 1996;16:6878–6885. [PubMed: 8824326]
- Liu L, Chang GQ, Jiao YQ, Simon SA. Neuronal nicotinic acetylcholine receptors in rat trigeminal ganglia. *Brain Res* 1998;809:238–245. [PubMed: 9853116]
- Liu Q, Huang Y, Xue F, Simard A, DeChon J, Li G, Zhang J, Lucero L, Wang M, Sierks M, et al. A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. *J Neurosci* 2009;29:918–929. [PubMed: 19176801]
- Liu Q, Melnikova IN, Hu M, Gardner PD. Cell type-specific activation of neuronal nicotinic acetylcholine receptor subunit genes by Sox10. *J Neurosci* 1999;19:9747–9755. [PubMed: 10559384]
- Lustig LR, Peng H, Hiel H, Yamamoto T, Fuchs PA. Molecular cloning and mapping of the human nicotinic acetylcholine receptor alpha10 (CHRNA10). *Genomics* 2001;73:272–283. [PubMed: 11350119]
- Mercer EH, Hoyle GW, Kapur RP, Brinster RL, Palmiter RD. The dopamine beta-hydroxylase gene promoter directs expression of E. coli lacZ to sympathetic and other neurons in adult transgenic mice. *Neuron* 1991;7:703–716. [PubMed: 1742021]
- Paxinos, G.; Franklin, KBJ. *The Mouse Brain in Stereotaxic Coordinates*. 2nd ed.. Academic Press; San Diego: 2001.
- Perl O, Ilani T, Strous RD, Lapidus R, Fuchs S. The alpha7 nicotinic acetylcholine receptor in schizophrenia: decreased mRNA levels in peripheral blood lymphocytes. *Faseb J* 2003;17:1948–1950. [PubMed: 12897067]
- Perry EK, Martin-Ruiz CM, Court JA. Nicotinic receptor subtypes in human brain related to aging and dementia. *Alcohol* 2001;24:63–68. [PubMed: 11522424]
- Phi-Van L, Stratling WH. Dissection of the ability of the chicken lysozyme gene 5' matrix attachment region to stimulate transgene expression and to dampen position effects. *Biochemistry* 1996;35:10735–10742. [PubMed: 8718863]
- Richardson CE, Morgan JM, Jasani B, Green JT, Rhodes J, Williams GT, Lindstrom J, Wonnacott S, Thomas GA, Smith V. Megacystis-microcolon-intestinal hypoperistalsis syndrome and the absence of the alpha3 nicotinic acetylcholine receptor subunit. *Gastroenterology* 2001;121:350–357. [PubMed: 11487544]
- Rust G, Burgunder JM, Lauterburg TE, Cachelin AB. Expression of neuronal nicotinic acetylcholine receptor subunit genes in the rat autonomic nervous system. *Eur J Neurosci* 1994;6:478–485. [PubMed: 8019684]
- Schuller HM. Neurotransmission and cancer: implications for prevention and therapy. *Anti-Cancer Drugs* 2008;19:655–671. [PubMed: 18594207]
- Schuller HM. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? *Nat Rev Cancer* 2009;9:195–205. [PubMed: 19194381]
- Silver AA, Shytle RD, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR. Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. *J Clin Psychiatry* 2001;62:707–714. [PubMed: 11681767]
- Simon D, Madison J, Conery A, Thompson-Peer K, Soskis M, Ruvkun G, Kaplan J, Kim J. The microRNA miR-1 regulates a MEF-2-dependent retrograde signal at neuromuscular junctions. *Cell* 2008;133:903–915. [PubMed: 18510933]
- Song P, Sekhon HS, Fu XW, Maier M, Jia Y, Duan J, Proskosil BJ, Gravett C, Lindstrom J, Mark GP, et al. Activated cholinergic signaling provides a target in squamous cell lung carcinoma. *Cancer Res* 2008;68:4693–4700. [PubMed: 18559515]
- Spindel ER. Neuronal nicotinic acetylcholine receptors: not just in brain. *Am J Physiol Lung Cell Mol Physiol* 2003;285:L1201–L1202. [PubMed: 14604850]
- Steen KH, Reeh PW. Actions of cholinergic agonists and antagonists on sensory nerve endings in rat skin, in vitro. *J Neurophysiol* 1993;70:397–405. [PubMed: 8103089]
- Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR, Scheffer IE, Berkovic SF. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. *Nat Genet* 1995;11:201–203. [PubMed: 7550350]

- Sucher NJ, Cheng TP, Lipton SA. Neural nicotinic acetylcholine responses in sensory neurons from postnatal rat. *Brain Res* 1990;533:248–254. [PubMed: 2289141]
- Taranda J, Maison SF, Ballesterio JA, Katz E, Savino J, Vetter DE, Boulter J, Liberman MC, Fuchs PA, Elgoyhen AB. A point mutation in the hair cell nicotinic cholinergic receptor prolongs cochlear inhibition and enhances noise protection. *PLOS Biol* 2009;7:1–13.
- Teaktong T, Graham A, Court J, Perry R, Jaros E, Johnson M, Hall R, Perry E. Alzheimer's disease is associated with a selective increase in $\alpha 7$ nicotinic acetylcholine receptor immunoreactivity in astrocytes. *Glia* 2003;41:207–211. [PubMed: 12509811]
- Valor LM, Campos-Caro A, Carrasco-Serrano C, Ortiz JA, Ballesta JJ, Criado M. Transcription factors NF-Y and Sp1 are important determinants of the promoter activity of the bovine and human neuronal nicotinic receptor beta 4 subunit genes. *J Biol Chem* 2002;277:8866–8876. [PubMed: 11742001]
- Vinclair MA, Eisenach JC. Immunocytochemical localization of the $\alpha 3$, $\alpha 4$, $\alpha 5$, $\alpha 7$, $\beta 2$, $\beta 3$ and $\beta 4$ nicotinic acetylcholine receptor subunits in the locus coeruleus of the rat. *Brain Res* 2003;974:25–36. [PubMed: 12742621]
- Wang N, Orr-Urtreger A, Korczyn AD. The role of neuronal nicotinic acetylcholine receptor subunits in autonomic ganglia: lessons from knockout mice. *Prog Neurobiol* 2002;68:341–360. [PubMed: 12531234]
- Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. *Brit J Pharmacol* 2008;154:1558–1571. [PubMed: 18500366]
- Whitehouse PJ, Martino AM, Marcus KA, Zweig RM, Singer HS, Price DL, Kellar KJ. Reductions in acetylcholine and nicotine binding in several degenerative diseases. *Arch Neurol* 1988;45:722–724. [PubMed: 3390025]
- Winzer-Serhan UH, Leslie FM. Codistribution of nicotinic acetylcholine receptor subunit $\alpha 3$ and $\beta 4$ mRNAs during rat brain development. *J Comp Neurol* 1997;386:540–554. [PubMed: 9378850]
- Xu X, Scott MM, Deneris ES. Shared long-range regulatory elements coordinate expression of a gene cluster encoding nicotinic receptor heteromeric subtypes. *Mol Cell Biol* 2006;26:5636–5649. [PubMed: 16847319]
- Yang X, Fyodorov D, Deneris ES. Transcriptional analysis of acetylcholine receptor $\alpha 3$ gene promoter motifs that bind Sp1 and AP2. *J Biol Chem* 1995;270:8514–8520. [PubMed: 7721749]
- Yang X, McDonough J, Fyodorov D, Morris M, Wang F, Deneris ES. Characterization of an acetylcholine receptor $\alpha 3$ gene promoter and its activation by the POU domain factor SCIP/Tst-1. *J Biol Chem* 1994;269:10252–10264. [PubMed: 8144606]
- Yuan JS, Burris J, Stewart NR, Mentewab A, Stewart NS. Statistical tools for transgene copy number estimation based on real-time PCR. *BMC Bioinformatics* 2007;8:S6. [PubMed: 18047729]
- Zhou Y, Deneris E, Zigmond RE. Differential regulation of levels of nicotinic receptor subunit transcripts in adult sympathetic neurons after axotomy. *J Neurobiol* 1998;34:164–178. [PubMed: 9468387]
- Zoli M, Le Novère N, Hill JA Jr, Changeux JP. Developmental regulation of nicotinic ACh receptor subunit mRNAs in the rat central and peripheral nervous systems. *J Neurosci* 1995;15:1912–1939. [PubMed: 7891142]

Figure 1.

The nACh receptor $\beta 4$ subunit promoter region used for transgenesis. **A.** The $\beta 4/\alpha 3/\alpha 5$ gene cluster. The 2.3-kb *SacI*/*HindIII* fragment of the $\beta 4$ promoter region is indicated on the left. Arrows indicate direction of transcription. The nucleotide positions of the *SacI* and *HindIII* sites are relative to the major transcription initiation site. **B.** Structure of the linearized construct, pSGB4SH, used to generate transgenic animals. MAR = matrix attachment region, NLS = nuclear localization sequence. **C.** Nucleotide sequences of the CT and CA boxes of the $\beta 4$ promoter region. **D.** The vector, pSGMAR, and pSGB4SH were transfected into PC12 cells along with a luciferase construct in which the SV40 promoter drives expression of the firefly luciferase gene. Cells were treated with NGF (100 ng/ml for 2 days) as indicated. β -Gal activity was normalized to luciferase activity to correct for differences in transfection efficiencies. Error bars represent standard deviations of the means.

Figure 2.

nACh receptor $\beta 4$ subunit promoter activity in the central nervous system of ED18.5 transgenic animals. Sagittal sections of transgenic (A, C, E, G, I and K) and non-transgenic (B, D, F, H, J and L) ED18.5 mouse brain and spinal cord are shown. The sections were stained for β -gal activity and counter-stained with Neutral Red. Note that β -gal staining is restricted to nuclei as the $\beta 4$ /lacZ transgene contains a nuclear localization signal (see Fig. 1B). A and B, cortex (IZ = intermediate zone, VZ = ventricular zone); C and D, medulla oblongata (M); E and F, pons (P); G and H, upper cervical region of the spinal cord; I and J, mid-thoracic region of the spinal cord; K and L, mid-lumbar region of the spinal cord. Arrows in panels G, I and K indicate β -gal-expressing cells.

Figure 3. nACh receptor $\beta 4$ subunit promoter activity in spinal ganglia of ED18.5 transgenic animals. Sagittal sections of transgenic ED18.5 animals were stained for β -gal activity and counterstained with Neutral Red. A, dorsal root ganglion (DRG); B, cervical dorsal root ganglion (CDRG); C, lumbar root ganglion (LRG); D, cervical root ganglion (CRG). Arrows in panels C and D indicate β -gal-expressing cells.

Figure 4.

nACh receptor $\beta 4$ subunit promoter activity in the intestine and tongue of ED18.5 transgenic animals. Sagittal sections of transgenic (A and C) and non-transgenic (B and D) ED18.5 animals were stained for β -gal activity and counter-stained with Neutral Red. A and B, intestine; C and D, tongue. β -gal staining of the tongue appears to be restricted to or near the longitudinal intrinsic muscle (arrows indicate β -gal-expressing cells).

Figure 5. nACh receptor $\beta 4$ subunit promoter activity in the forebrain and cortical regions of PD30 transgenic animals. Coronal sections of transgenic (A, C, E, G and I) and non-transgenic (B, D, F, H and J) PD30 mouse brains are shown. The sections were stained for β -gal activity and counter-stained with Neutral Red. A and B, layer 5 of the cortex ("5"); C and D, piriform cortex (Pir); E and F, frontal association cortex (FrA); G and H, caudate putamen (Cpu); I and J, cingulate/retrosplenial cortex (Cg/Rs). Arrows in panels E, G and I indicate β -gal-expressing cells

Figure 6.

nACh receptor $\beta 4$ subunit promoter activity in the central nervous system of PD30 transgenic animals. Coronal sections of transgenic (A, C, E and G) and non-transgenic (B, D, F and H) PD30 mouse brains are shown. The sections were stained for β -gal activity and counter-stained with Neutral Red. A and B, hippocampus (CA1) and dentate gyrus (DG); C and D, medial (MHb) and lateral (LHb) habenula and paraventricular thalamic nucleus (PV); E and F, ventral anterior thalamic nucleus (VA); G and H, posteromedial cortical amygdaloid nucleus (PMCo). Arrows in panels A, C and G indicate β -gal-expressing cells.

Figure 7.

The nACh receptor $\beta 4$ subunit promoter directs neuron-specific gene expression. Triple immunofluorescence was done on coronal sections of transgenic (TG) and non-transgenic (WT) PD30 mouse brains. A, cortex; B, thalamus; C, amygdala. GFAP = glial fibrillary acid protein (yellow arrows), NeuN = neuron-specific nuclear marker, β -gal = β -galactosidase. Overlap of the three immunostained sections indicates specific β -gal staining in neuronal nuclei (white arrows). β -gal histochemistry (right panels) was done to confirm β -gal activity in the transgenic animals. Note: There was no GFAP staining in the thalamus (panel B).

Table 1 β 4/lacZ transgene expression in the central nervous system of ED18.5 embryos

Central Nervous System Region	30	39	54	447
Cerebral Cortex	–	–	++++	++
Piriform Cortex	–	–	+	+
Subiculum	–	–	++	+
Lateral Habenula	–	–	+	+
Medial Habenula	–	–	+	+
Medulla Oblongata	–	–	++	+
Anterior Pontine Area	–	–	++	+
Posterior Pontine Area	–	–	++	+
Pons	–	–	++	++
Pineal Gland	–	–	–	–
Thalamus	–	–	–	+
Ventral Spinal Cord	–	–	+	++
Dorsal Spinal Cord	–	–	+	++

Expression levels were scored as follows: –, no expression; +, low level; ++, intermediate level; +++, very high level.

Table 2 β 4/lacZ transgene expression outside the central nervous system of ED18.5 embryos

Tissue	30	39	54	447
Retina	+	–	+	+
Cervical Root Ganglia	–	–		
Ventral	–	–	+	++
Dorsal	–	–	+	++
Thoracic Root Ganglia	–	–		
Ventral	–	–	+	+
Dorsal	–	–	+	+
Lumbar Root Ganglia	–	–		
Ventral	–	–	+	+
Dorsal	–	–	+	+
Trigeminal Ganglia	–	–	+	–
Intestine	–	++++	+++	–
Tongue	++	–	+	–
Lips	+	–	+	+

Expression levels were scored as follows: –, no expression; +, low level; ++, intermediate level; +++, high level; +++++, very high level.

Table 3 β 4/lacZ transgene expression in the central nervous system of PD30 animals

Brain Region	30	39	54	447
<u>Forebrain/Cortex</u>				
layer 1	–	+	+	+
layer 2	–	+	+	–
layer 3	–	–	+	+
layer 5	+	++	++++	++
anterior olfactory nucleus	–	++	+	+
basal nucleus (Meynert)	+	+	–	+
caudate putamen (striatum)	+	+	++	++
lateral globus pallidus	–	+	+	+
olfactory bulb	+	+	++	+
olfactory tubercle	+	–	+	++
agranular insular cortex	+	+	+++	+
auditory cortex	–	+	++	+
cingulate cortex, area 1	–	+	++	++
cingulate/retrosplenial cortex	+	+	+	–
cortex-amygdala transition zone	–	+	+	+
dorsal endopiriform nucleus	+	+	++++	++
entorhinal cortex	+	+	+++	+
frontal association cortex	+	+	++	++
granular insular cortex	–	+	+	+
orbital cortex	+	+	+++	++
primary motor cortex	–	+	++	++
secondary motor cortex	+	+	++	++
piriform cortex	++	+++	++++	+++
perirhinal cortex	+	+	+++	+
prelimbic cortex	+	–	+++	++
retrosplenial agranular cortex	+	+	+	+
primary somatosensory cortex	+	+	++	++
secondary somatosensory cortex	+	+	++	+
temporal association cortex	–	+	+++	+
primary visual cortex	+	+	+	++
secondary visual cortex	–	+	+	+
<u>Hippocampus/Corpus Callosum</u>				
parasubiculum	–	+	+	+
presubiculum	–	+	+	+
subiculum	–	++	++++	+
molecular layer of the dentate gyrus	–	++++	++	++
oriens layer of the hippocampus	–	++	+	+
<u>Habenular Nuclei</u>				
lateral habenular nucleus	+	+	+	+

Brain Region	30	39	54	447
medial habenular nucleus	–	+++	++	+
<u>Preoptic Area</u>				
lateral preoptic area	+	+	+	+
medial preoptic area	+	+	+	+
median preoptic nucleus	+	+	–	+
medial preoptic nucleus, medial part	–	+	+	+
<u>Thalamus</u>				
anteromedial thalamic nucleus	–	++	+	+
basomedial amygdaloid nucleus, anterior part	+	+	++	+
caudal interstitial nucleus of the medial, longitudinal fasciculus	–	+	++	+
central medial thalamic nucleus	–	+	+	+
dysgranular insular cortex	–	+	++	+
dorsolateral orbital cortex	+	+	++	+
dorsal penduncular cortex	+	+	+	++
gustatory thalamic nucleus	+	+	+	–
laterodorsal thalamic nucleus, dorsomedial part	+	+	+	–
lateral posterior thalamic nucleus, mediorostral part	–	+	+	+
mediodorsal thalamic nucleus	+	+	+	+
medial geniculate nucleus	–	++	++	+
posterior thalamic nuclear group	–	+	++++	+
paratenial thalamic nucleus	–	+	+	+
paraventricular thalamic nucleus	+	+	++	+
precommissural nucleus	+	+	+	+
reuniens thalamic nucleus	–	+	+	+
stria medullaris of the thalamus	–	+	+	+
ventral anterior thalamic nucleus	+	+	+	+
ventrolateral thalamic nucleus	–	+	+	+++
ventromedial thalamic nucleus	–	+	+	+
ventral posteromedial thalamic nucleus	–	+	+	+
<u>Hypothalamus</u>				
dorsomedial hypothalamic nucleus	++	+	+	–
lateral hypothalamic area	+++	+	+	+
medial forebrain bundle	+	+	+	–
perifornical nucleus	+	+	+	–
posterior hypothalamic area	+	+	+	–
ventromedial hypothalamic nucleus	+	+	+	+
<u>Amygdala</u>				
anterior amygdaloid area	–	+	+	+
anterior cortical amygdaloid nucleus	–	+	+	+
medial amygdaloid nucleus	+	+	+	+
posterolateral cortical amygdaloid nucleus	–	++	+++	++

Brain Region	30	39	54	447
posteromedial cortical amygdaloid nucleus	+	++	++	+
<u>Other Midbrain Structures</u>				
dorsolateral periaqueductal gray	+	+	–	+
deep mesencephalic nucleus	+	+	+	–
inferior colliculus	+	+	++	+
retroparafascicular nucleus	+	+	+	–
subbrachial nucleus	+	+	+	+
superior colliculus	+	+	–	+
<u>Pons</u>				
laterodorsal tegmental nucleus	+	+	+	–
lateral mammillary nucleus	+	+	+	–
lateral parabrachial nucleus, ventral part	+	+	–	+
medial lemniscus	+	++	–	+

Expression levels were scored as follows: –, no expression; +, low level; ++, intermediate level; +++, high level; +++++, very high level.